Moomoo AI 已提取核心訊息
Altamira Therapeutics Ltd., a Bermuda-incorporated company, has successfully completed the partial spin-off of its Bentrio business, selling a 51% stake in its subsidiary Altamira Medica AG to a Swiss private equity investor as reported on January 19, 2024. The transaction, which closed on November 21, 2023, is part of Altamira's strategic repositioning to focus on its RNA delivery technology. The company received approximately $2.3 million in cash for the majority stake and retained a 49% interest in Medica. Additionally, Altamira is entitled to 25% of Medica's future gross licensing income. The deal also included the sale of Auris Medical Pty Ltd and a cash contribution to Medica's capital. Altamira anticipates a financial gain of about $5.2 million from the transaction, which will be recorded in accordance with International Financial Reporting Standards. The unaudited pro forma financial information reflecting the transaction has been filed with the U.S. Securities and Exchange Commission.
Altamira Therapeutics Ltd., a Bermuda-incorporated company, has successfully completed the partial spin-off of its Bentrio business, selling a 51% stake in its subsidiary Altamira Medica AG to a Swiss private equity investor as reported on January 19, 2024. The transaction, which closed on November 21, 2023, is part of Altamira's strategic repositioning to focus on its RNA delivery technology. The company received approximately $2.3 million in cash for the majority stake and retained a 49% interest in Medica. Additionally, Altamira is entitled to 25% of Medica's future gross licensing income. The deal also included the sale of Auris Medical Pty Ltd and a cash contribution to Medica's capital. Altamira anticipates a financial gain of about $5.2 million from the transaction, which will be recorded in accordance with International Financial Reporting Standards. The unaudited pro forma financial information reflecting the transaction has been filed with the U.S. Securities and Exchange Commission.
據2024年1月19日報道，百慕大註冊公司Altamira Therapeutics Ltd. 已成功完成其Bentrio業務的部分分割，將其子公司Altamira Medica AG的51％股份出售給了一位瑞士私募股權投資者。該交易於2023年11月21日完成，是阿爾塔米拉戰略調整的一部分，旨在專注於其RNA交付技術。該公司獲得了約230萬澳元的現金作爲多數股權，並保留了Medica49％的權益。此外，阿爾塔米拉有權獲得Medica未來許可總收入的25％。該交易還包括出售Auris Medical Pty Ltd和對Medica資本的現金捐款。阿爾塔米拉預計，該交易將帶來約520萬美元的財務收益，該收益將按照《國際財務報告準則》進行記錄。反映該交易的未經審計的預計財務信息已提交給美國證券交易委員會。
據2024年1月19日報道，百慕大註冊公司Altamira Therapeutics Ltd. 已成功完成其Bentrio業務的部分分割，將其子公司Altamira Medica AG的51％股份出售給了一位瑞士私募股權投資者。該交易於2023年11月21日完成，是阿爾塔米拉戰略調整的一部分，旨在專注於其RNA交付技術。該公司獲得了約230萬澳元的現金作爲多數股權，並保留了Medica49％的權益。此外，阿爾塔米拉有權獲得Medica未來許可總收入的25％。該交易還包括出售Auris Medical Pty Ltd和對Medica資本的現金捐款。阿爾塔米拉預計，該交易將帶來約520萬美元的財務收益，該收益將按照《國際財務報告準則》進行記錄。反映該交易的未經審計的預計財務信息已提交給美國證券交易委員會。
有用
沒用